• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
MENUMENU
MENUMENU
  • Home
  • About
    • Contact Us
    • FlaglerLive Board of Directors
    • Comment Policy
    • Mission Statement
    • Our Values
    • Privacy Policy
  • Live Calendar
  • Submit Obituary
  • Submit an Event
  • Support FlaglerLive
  • Advertise on FlaglerLive (386) 503-3808
  • Search Results

FlaglerLive

No Bull, no Fluff, No Smudges

MENUMENU
  • Flagler
    • Flagler County Commission
    • Beverly Beach
    • Economic Development Council
    • Flagler History
    • Mondex/Daytona North
    • The Hammock
    • Tourist Development Council
  • Palm Coast
    • Palm Coast City Council
    • Palm Coast Crime
  • Bunnell
    • Bunnell City Commission
    • Bunnell Crime
  • Flagler Beach
    • Flagler Beach City Commission
    • Flagler Beach Crime
  • Cops/Courts
    • Circuit & County Court
    • Florida Supreme Court
    • Federal Courts
    • Flagler 911
    • Fire House
    • Flagler County Sheriff
    • Flagler Jail Bookings
    • Traffic Accidents
  • Rights & Liberties
    • Fourth Amendment
    • First Amendment
    • Privacy
    • Second Amendment
    • Seventh Amendment
    • Sixth Amendment
    • Sunshine Law
    • Third Amendment
    • Religion & Beliefs
    • Human Rights
    • Immigration
    • Labor Rights
    • 14th Amendment
    • Civil Rights
  • Schools
    • Adult Education
    • Belle Terre Elementary
    • Buddy Taylor Middle
    • Bunnell Elementary
    • Charter Schools
    • Daytona State College
    • Flagler County School Board
    • Flagler Palm Coast High School
    • Higher Education
    • Imagine School
    • Indian Trails Middle
    • Matanzas High School
    • Old Kings Elementary
    • Rymfire Elementary
    • Stetson University
    • Wadsworth Elementary
    • University of Florida/Florida State
  • Economy
    • Jobs & Unemployment
    • Business & Economy
    • Development & Sprawl
    • Leisure & Tourism
    • Local Business
    • Local Media
    • Real Estate & Development
    • Taxes
  • Commentary
    • The Conversation
    • Pierre Tristam
    • Diane Roberts
    • Guest Columns
    • Byblos
    • Editor's Blog
  • Culture
    • African American Cultural Society
    • Arts in Palm Coast & Flagler
    • Books
    • City Repertory Theatre
    • Flagler Auditorium
    • Flagler Playhouse
    • Flagler Youth Orchestra
    • Jacksonville Symphony Orchestra
    • Palm Coast Arts Foundation
    • Special Events
  • Elections 2024
    • Amendments and Referendums
    • Presidential Election
    • Campaign Finance
    • City Elections
    • Congressional
    • Constitutionals
    • Courts
    • Governor
    • Polls
    • Voting Rights
  • Florida
    • Federal Politics
    • Florida History
    • Florida Legislature
    • Florida Legislature
    • Ron DeSantis
  • Health & Society
    • Flagler County Health Department
    • Ask the Doctor Column
    • Health Care
    • Health Care Business
    • Covid-19
    • Children and Families
    • Medicaid and Medicare
    • Mental Health
    • Poverty
    • Violence
  • All Else
    • Daily Briefing
    • Americana
    • Obituaries
    • News Briefs
    • Weather and Climate
    • Wildlife

Will Corbevax, a Patent-Free Covid Vaccine, Be a Game-Changer?

January 19, 2022 | FlaglerLive | Leave a Comment

corbevax
Patent-free.

By Maureen Ferran

The world now has a new COVID-19 vaccine in its arsenal, and at a fraction of the cost per dose.




Two years into the COVID-19 pandemic, the world has seen over 314 million infections and over 5.5 million deaths worldwide. Approximately 60% of the world population has received at least one dose of a COVID-19 vaccine. But there is still a glaring and alarming gap in global access to these vaccines. As a virologist who has followed this pandemic closely, I contend that this vaccine inequity should be of grave concern to everyone.

If the world has learned anything from this pandemic, it’s that viruses do not need a passport. And yet approximately 72% of vaccine doses were administered in high- and upper-middle-income countries – and only 1% in low-income countries. Wealthy countries are giving boosters, and even fourth doses, while first and second doses are not available to many worldwide.

But there is hope that a new vaccine called CORBEVAX will help close this vaccination gap.



How does the CORBEVAX vaccine work?

All COVID-19 vaccines teach the immune system how to recognize the virus and prepare the body to mount an attack. The CORBEVAX vaccine is a protein subunit vaccine. It uses a harmless piece of the spike protein from the coronavirus that causes COVID-19 to stimulate and prepare the immune system for future encounters with the virus.

Unlike the three vaccines approved in the U.S. – Pfizer and Moderna’s mRNA vaccines and Johnson & Johnson’s viral vector vaccine, which provide the body instructions on how to produce the spike protein – CORBEVAX delivers the spike protein to the body directly. Like those other approved COVID-19 mRNA vaccines, CORBEVAX also requires two doses.

How was CORBEVAX developed?

CORBEVAX was developed by the co-directors of the Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine, Drs. Maria Elena Bottazzi and Peter Hotez.




During the 2003 SARS outbreak, these researchers created a similar type of vaccine by inserting the genetic information for a portion of the SARS virus spike protein into yeast to produce large amounts of the protein. After isolating the virus spike protein from the yeast and adding an adjuvant, which helps trigger an immune response, the vaccine was ready for use.

The first SARS epidemic was short-lived, and there was little need for Bottazzi and Hotez’s vaccine – until the virus that causes COVID-19, SARS-CoV-2, emerged in 2019. So they dusted off their vaccine and updated the spike protein to match that of SARS-CoV-2, creating the CORBEVAX vaccine.

A large U.S.-based clinical trial found the vaccine to be

safe, well tolerated and over 90% effective at preventing symptomatic infections. The vaccine received emergency use authorization in India, and other developing countries are expected to follow.

Interestingly, the group at Baylor was not able to drum up interest or funding in the U.S. for their vaccine. Instead, newer technologies such as mRNA vaccines raced ahead, even though Bottazzi and Hotez’s vaccine design was more advanced, thanks to their previous work during the 2003 SARS and 2012 MERS outbreaks.

A vaccine built for the world

Protein subunit vaccines have an advantage over mRNA vaccines in that they can be readily produced using well-established recombinant DNA technology that is relatively inexpensive and fairly easy to scale up. A similar protein recombinant technology that’s been around for 40 years has been used for the Novavax COVID-19 vaccine, which is available for use in 170 countries, and the recombinant hepatitis B vaccine.

This vaccine can be produced at a much larger scale because appropriate manufacturing facilities are already available. Also key to global access is that CORBEVAX can be stored in a regular refrigerator. Therefore, it is possible to produce millions of doses rapidly and distribute them relatively easily. In comparison, producing mRNA vaccines is more expensive and complicated because they are based on newer technologies, rely on highly skilled workers and often require ultralow temperatures for storage and transport.




Another major difference is that the CORBEVAX vaccine was developed with global vaccine access in mind. The goal was to make a low-cost, easy-to-produce and -transport vaccine using a well-tested and safe method. Key to this, the researchers were not concerned with intellectual property or financial benefit. The vaccine was produced without significant public funding; the US$7 million needed for development was provided by philanthropists.

COBREVAX is currently licensed patent-free to Biological E. Limited (BioE), India’s largest vaccine maker, which plans to manufacture at least 100 million doses per month starting in February 2022. This patent-free arrangement means that other low- and middle-income countries can produce and distribute this cheap, stable and relatively easy-to-scale vaccine locally.

Combined, this means that CORBEVAX is one of the cheapest vaccines currently available. How well it works against the omicron variant is under investigation. However, the CORBEVAX story can be used as a model to address vaccine inequity when it is necessary to vaccinate the world population – against COVID-19 and other diseases on the horizon.

The necessity of vaccine equity

There are many reasons global access to vaccines is inequitable. For example, the governments of wealthy nations purchase vaccines in advance, which limits supply. While developing countries do have vaccine production capacity, low- and middle-income countries in Africa, Asia and Latin America still need to be able to afford the cost of placing orders.

The Indian government has ordered 300 million doses of CORBEVAX, and BioE plans to produce more than 1 billion shots for people in developing countries. For context, the U.S. and other G7 nations have pledged to donate over 1.3 billion doses of COVID vaccines, yet only 591 million doses have been shipped. These numbers mean that if BioE is able to produce 1.3 billion doses of CORBEVAX as planned, this vaccine will reach more people than those vaccinated by what’s been donated and shipped by the wealthiest nations.

As the omicron variant has shown, new variants can spread across the world quickly and are much more likely to develop in unvaccinated people and continue to emerge as long as global vaccination rates remain low. It is unlikely that boosters will end this pandemic. Rather, developing globally accessible vaccines like CORBEVAX represent an important first step in vaccinating the world and ending this pandemic.

Maureen Ferran is Associate Professor of Biology at the Rochester Institute of Technology.

The Conversation

The Conversation arose out of deep-seated concerns for the fading quality of our public discourse and recognition of the vital role that academic experts could play in the public arena. Information has always been essential to democracy. It’s a societal good, like clean water. But many now find it difficult to put their trust in the media and experts who have spent years researching a topic. Instead, they listen to those who have the loudest voices. Those uninformed views are amplified by social media networks that reward those who spark outrage instead of insight or thoughtful discussion. The Conversation seeks to be part of the solution to this problem, to raise up the voices of true experts and to make their knowledge available to everyone. The Conversation publishes nightly at 9 p.m. on FlaglerLive.
See the Full Conversation Archives

Support FlaglerLive's End of Year Fundraiser
Thank you readers for getting us to--and past--our year-end fund-raising goal yet again. It’s a bracing way to mark our 15th year at FlaglerLive. Our donors are just a fraction of the 25,000 readers who seek us out for the best-reported, most timely, trustworthy, and independent local news site anywhere, without paywall. FlaglerLive is free. Fighting misinformation and keeping democracy in the sunshine 365/7/24 isn’t free. Take a brief moment, become a champion of fearless, enlightening journalism. Any amount helps. We’re a 501(c)(3) non-profit news organization. Donations are tax deductible.  
You may donate openly or anonymously.
We like Zeffy (no fees), but if you prefer to use PayPal, click here.

Reader Interactions

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Conner Bosch law attorneys lawyers offices palm coast flagler county
  • grand living realty
  • politis matovina attorneys for justice personal injury law auto truck accidents

Primary Sidebar

  • grand living realty
  • politis matovina attorneys for justice personal injury law auto truck accidents

Recent Comments

  • JC on David Jolly Makes It Official: He’s Running for Governor as Newly-Minted Centrist Democrat
  • Ed P on The Daily Cartoon and Live Briefing: Thursday, June 5, 2025
  • NJ on Poland Veers Right, a Bad Omen for EU, Ukraine and Women
  • Hmmm on Palm Coast Council Approves Hiring of Sheriff’s Chief Strobridge on 4-1 Vote; Staly Addresses Risks
  • Roger on New Cell Towers Planned for Palm Coast Parkway East of I-95 and in Seminole Woods, as Business and Safety ‘Necessity’
  • Skibum on The Daily Cartoon and Live Briefing: Thursday, June 5, 2025
  • Me on David Jolly Makes It Official: He’s Running for Governor as Newly-Minted Centrist Democrat
  • Nobody on NOAA Cuts Are Putting Our Coastal Communities At Risk
  • Judith G. Michaud on David Jolly Makes It Official: He’s Running for Governor as Newly-Minted Centrist Democrat
  • PC stinks of corruption on Palm Coast Council Approves Hiring of Sheriff’s Chief Strobridge on 4-1 Vote; Staly Addresses Risks
  • Sunny on Palm Coast Council Approves Hiring of Sheriff’s Chief Strobridge on 4-1 Vote; Staly Addresses Risks
  • Maxie on Flagler Beach Will Consider Selling Ocean Palm Golf Club to Leaseholder, With Conditional Milestones
  • Samuel L. Bronkowitz on Led by Paul Renner, Board of Governors Rejects Ono’s Appointment as President of UF Over Past Views on DEI
  • Devils way on Palm Coast Council Approves Hiring of Sheriff’s Chief Strobridge on 4-1 Vote; Staly Addresses Risks
  • [email protected] on The Daily Cartoon and Live Briefing: Thursday, June 5, 2025
  • Truth bomb on Florida Law Restricting Ballot Initiatives Survives Court Challenge

Log in